MicroRNA-206 Suppresses Growth and Metastasis of Breast Cancer Stem Cells Via Blocking EVI-1-mediated CALR Expression

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Sep 22

PMID 36136972

Authors

Dapeng Sun

Chenguang Li

Fengxiang Zhang

Affiliations

Soon will be listed here.

Abstract

Aim to investigate the effect of miR-206 on the growth and metastasis of breast cancer stem cells and clarify the precise mechanism of miR-206 on EVI-1-mediated CALR expression in driving malignant phenotype. Our results showed that miR-206 mimics suppressed CALR expression, inhibited the proliferation and metastasis ability of breast cancer stem cells and finally induced cellular apoptosis. Over-expression of CALR could effectively attenuate the cytotoxic effect of miR-206. Further studies demonstrated that EVI-1 could be served as a key regulator of miR206-mediated CALR expression. Elevation of EVI-1 can reverse the function of miR-206 on induction of CALR.

Citing Articles

MicroRNAs: A Link between Mammary Gland Development and Breast Cancer.

Wu D, Thompson L, Comelli E Int J Mol Sci. 2022; 23(24).

PMID: 36555616 PMC: 9786715. DOI: 10.3390/ijms232415978.

References

Villar Balboa I, Regi Bosque M . [Breast cancer in a male patient]. Semergen. 2016; 42(7):e110-e112. DOI: 10.1016/j.semerg.2015.12.018. View

Lee H, Lim C, Cheong Y, Singh M, Gam L . Comparison of protein expression profiles of different stages of lymph nodes metastasis in breast cancer. Int J Biol Sci. 2012; 8(3):353-62. PMC: 3291852. DOI: 10.7150/ijbs.3157. View

Angadi P, Patil P, Angadi V, Mane D, Shekar S, Hallikerimath S . Immunoexpression of Epithelial Mesenchymal Transition Proteins E-Cadherin, β-Catenin, and N-Cadherin in Oral Squamous Cell Carcinoma. Int J Surg Pathol. 2016; 24(8):696-703. DOI: 10.1177/1066896916654763. View

Liu F, Zhao X, Qian Y, Zhang J, Zhang Y, Yin R . MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway. Biomed Pharmacother. 2017; 96:229-237. DOI: 10.1016/j.biopha.2017.08.145. View

Bhandari A, Zheng C, Sindan N, Sindan N, Quan R, Xia E . COPB2 is up-regulated in breast cancer and plays a vital role in the metastasis via N-cadherin and Vimentin. J Cell Mol Med. 2019; 23(8):5235-5245. PMC: 6652939. DOI: 10.1111/jcmm.14398. View

Eric-Nikolic A, Milovanovic Z, Sanchez D, Pekarikova A, Dzodic R, Matic I . Overexpression of calreticulin in malignant and benign breast tumors: relationship with humoral immunity. Oncology. 2012; 82(1):48-55. DOI: 10.1159/000335267. View

Liu Y, Liang B, Guan Y, You J, Zhu L, Chen X . Loss of N-cadherin is associated with loss of E-cadherin expression and poor outcomes of liver resection in hepatocellular carcinoma. J Surg Res. 2014; 194(1):167-76. DOI: 10.1016/j.jss.2014.09.031. View

Kotiyal S, Bhattacharya S . Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun. 2014; 453(1):112-6. DOI: 10.1016/j.bbrc.2014.09.069. View

Patel J, Appaiah H, Burnett R, Bhat-Nakshatri P, Wang G, Mehta R . Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene. 2010; 30(11):1290-301. DOI: 10.1038/onc.2010.510. View

10.

De Craene B, Berx G . Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13(2):97-110. DOI: 10.1038/nrc3447. View

11.

Kwak P, Iwasaki S, Tomari Y . The microRNA pathway and cancer. Cancer Sci. 2010; 101(11):2309-15. PMC: 11159795. DOI: 10.1111/j.1349-7006.2010.01683.x. View

12.

Liu X, Zhao D, Sun D, Wang Y, Li Y, Qiu F . Adenovirus-mediated delivery of CALR and MAGE-A3 inhibits invasion and angiogenesis of glioblastoma cell line U87. J Exp Clin Cancer Res. 2012; 31:8. PMC: 3337230. DOI: 10.1186/1756-9966-31-8. View

13.

Lu Y, Chen C, Wang B, Hsu W, Chen S, Chang K . Changes in tumor growth and metastatic capacities of J82 human bladder cancer cells suppressed by down-regulation of calreticulin expression. Am J Pathol. 2011; 179(3):1425-33. PMC: 3157280. DOI: 10.1016/j.ajpath.2011.05.015. View

14.

Wu X, Somlo G, Yu Y, Palomares M, Li A, Zhou W . De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med. 2012; 10:42. PMC: 3342150. DOI: 10.1186/1479-5876-10-42. View

15.

Yuan X, Wang X, Bi K, Jiang G . The role of EVI-1 in normal hematopoiesis and myeloid malignancies (Review). Int J Oncol. 2015; 47(6):2028-36. DOI: 10.3892/ijo.2015.3207. View

16.

Pasquinelli A . MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012; 13(4):271-82. DOI: 10.1038/nrg3162. View

17.

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

18.

Chen Q, Jiao D, Wu Y, Chen J, Wang J, Tang X . MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway. Oncotarget. 2016; 7(14):18247-61. PMC: 4951285. DOI: 10.18632/oncotarget.7570. View

19.

Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H . Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One. 2012; 7(10):e46670. PMC: 3467269. DOI: 10.1371/journal.pone.0046670. View

20.

Wu L, Wang T, He D, Li X, Jiang Y . miR-1 inhibits the proliferation of breast cancer stem cells by targeting EVI-1. Onco Targets Ther. 2018; 11:8773-8781. PMC: 6287527. DOI: 10.2147/OTT.S188836. View